HOME › COMPANIES › HARMONY BIOSCIENCES
EMERGING PUBLIC BIOTECH

HARMONY BIOSCIENCES (HRMY)

Plymouth Meeting, United States · North America
NEUROLOGY
RARE DISEASE
EMERGING PUBLIC BIOTECH
HEADQUARTERS
Plymouth Meeting, United States
TICKER
HRMY
SEGMENT
Emerging Public Biotech
THERAPY AREAS
Neurology, Rare Disease
KEY PRODUCTS
PRODUCTDETAILS
WAKIX—
COMPANY OVERVIEW

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and othe…

HARMONY BIOSCIENCES — FULL INTELLIGENCE

Live regulatory signals, patent cliffs, financials, tariff exposure and pipeline — all free on PharmaSignal.

OPEN PLATFORM →